<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id>
<journal-title>Frontiers in Pediatrics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pediatr.</abbrev-journal-title>
<issn pub-type="epub">2296-2360</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fped.2025.1652101</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatrics</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Development of mild encephalitis with a reversible splenial lesion prior to the diagnosis of Kawasaki disease: a pediatric case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yamanouchi</surname><given-names>Hirokazu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib>
<contrib contrib-type="author"><name><surname>Onoyama</surname><given-names>Sagano</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/3102043/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Marutani</surname><given-names>Kentaro</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Harada</surname><given-names>Nobutaka</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Ueno</surname><given-names>Yuji</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Kanemasa</surname><given-names>Hikaru</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/964666/overview" /><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Kira</surname><given-names>Ryutaro</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Kaneko</surname><given-names>Shuya</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/3147595/overview" /><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author"><name><surname>Shimizu</surname><given-names>Masaki</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/1441573/overview" /><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Hoshina</surname><given-names>Takayuki</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref><uri xlink:href="https://loop.frontiersin.org/people/3137111/overview" /><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib>
</contrib-group>
<aff id="aff1"><label><sup>1</sup></label><institution>Kawasaki Disease Center, Fukuoka Children&#x2019;s Hospital</institution>, <addr-line>Fukuoka</addr-line>, <country>Japan</country></aff>
<aff id="aff2"><label><sup>2</sup></label><institution>Department of Pediatric Neurology, Fukuoka Children&#x2019;s Hospital</institution>, <addr-line>Fukuoka</addr-line>, <country>Japan</country></aff>
<aff id="aff3"><label><sup>3</sup></label><institution>Department of Pediatric Infectious Diseases and Immunology, Fukuoka Children&#x2019;s Hospital</institution>, <addr-line>Fukuoka</addr-line>, <country>Japan</country></aff>
<aff id="aff4"><label><sup>4</sup></label><institution>Department of Pediatrics and Developmental Biology, Institute of Science Tokyo</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country></aff>
<aff id="aff5"><label><sup>5</sup></label><institution>Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country></aff>
<aff id="aff6"><label><sup>6</sup></label><institution>General Medical Department, Fukuoka Children&#x2019;s Hospital</institution>, <addr-line>Fukuoka</addr-line>, <country>Japan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p><bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1744113/overview">Stephen Aronoff</ext-link>, Temple University, United States</p></fn>
<fn fn-type="edited-by"><p><bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1114910/overview">Maria Vincenza Mastrolia</ext-link>, Meyer University Hospital, University of Florence, Italy</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/703956/overview">Maria Kostara</ext-link>, University Hospital of Ioannina, Greece</p></fn>
<corresp id="cor1"><label>&#x002A;</label><bold>Correspondence:</bold> Takayuki Hoshina <email>hoshina.t@fcho.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>13</day><month>08</month><year>2025</year></pub-date>
<pub-date pub-type="collection"><year>2025</year></pub-date>
<volume>13</volume><elocation-id>1652101</elocation-id>
<history>
<date date-type="received"><day>23</day><month>06</month><year>2025</year></date>
<date date-type="accepted"><day>28</day><month>07</month><year>2025</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2025 Yamanouchi, Onoyama, Marutani, Harada, Ueno, Kanemasa, Kira, Kaneko, Shimizu and Hoshina.</copyright-statement>
<copyright-year>2025</copyright-year><copyright-holder>Yamanouchi, Onoyama, Marutani, Harada, Ueno, Kanemasa, Kira, Kaneko, Shimizu and Hoshina</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Kawasaki disease (KD) rarely causes neurological complications. KD is diagnosed based on symptoms alone and can be very difficult to diagnose if other symptoms appear in febrile children before the main symptoms of KD. A 5-year-old boy with fever and consciousness disturbance was hospitalized and diagnosed with mild encephalitis/encephalopathy with reversible splenial lesion (MERS). The fever and consciousness disturbance resolved with intravenous methylprednisolone for 3 days (30&#x2005;mg/kg/day) and intravenous immunoglobulin (IVIG; 1&#x2005;g/kg/day) for 2 days, which was initiated as treatment for MERS. However, bilateral conjunctival injections, redness of the lips, and membranous desquamation of the fingers were observed, followed by recurrence of fever four days after the initial treatment. Echocardiography revealed dilation of the right coronary artery (RCA). The patient was diagnosed with incomplete KD and was treated with high-dose IVIG and oral aspirin based on the presence of four major KD symptoms and coronary artery dilation. After treatment, he showed defervescence, and the RCA showed no further dilation on echocardiography. Clinicians should recognize that the development of MERS may precede the diagnosis of KD in some patients. In addition, patients with MERS of unknown etiology, leukocytosis, and elevated serum CRP levels should be closely monitored because of the possibility of KD.</p>
</abstract>
<kwd-group>
<kwd>Kawasaki disease</kwd>
<kwd>mild encephalitis with a reversible splenial lesion</kwd>
<kwd>coronary artery abnormality</kwd>
<kwd>intravenous immunoglobulin</kwd>
<kwd>case report</kwd>
<kwd>presenting symptoms</kwd>
</kwd-group><counts>
<fig-count count="1"/>
<table-count count="1"/><equation-count count="0"/><ref-count count="15"/><page-count count="5"/><word-count count="0"/></counts><custom-meta-wrap><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>General Pediatrics and Pediatric Emergency Care</meta-value></custom-meta></custom-meta-wrap>
</article-meta>
</front>
<body><sec id="s1" sec-type="intro"><title>Introduction</title>
<p>Kawasaki disease (KD) is a systemic vasculitis of unknown origin that predominantly affects children under five years of age (<xref ref-type="bibr" rid="B1">1</xref>). KD is commonly complicated by cardiovascular diseases, including coronary artery abnormalities (CAAs), but it can also cause complications in other organs (<xref ref-type="bibr" rid="B2">2</xref>). Neurological complications associated with KD are relatively rare, with encephalopathy occurring in only 0.09&#x0025; of patients (<xref ref-type="bibr" rid="B3">3</xref>). KD is diagnosed on the basis of symptoms alone, which can be very difficult to diagnose if other symptoms appear in febrile children before the main symptoms of KD (e.g., rash, red eyes, strawberry tongue, enlarged lymph nodes in the neck, and swelling of the palms and soles) (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>We herein report the case of a pediatric patient who was hospitalized for fever and consciousness disturbance caused by mild encephalitis/encephalopathy with a reversible splenial lesion (MERS), characterized by a reversible lesion with homogenously reduced diffusion in the corpus callosum, which recovered almost completely within one month (<xref ref-type="bibr" rid="B4">4</xref>). Symptoms of KD emerged while the patient was receiving treatment for the MERS. It is clinically important to keep in mind the existence of KD, potentially presenting with MERS-like features, before the classic diagnostic criteria are met. In addition, we reviewed the characteristics of patients who developed MERS before the diagnosis of KD, including previously reported cases.</p>
</sec>
<sec id="s2"><title>Case report</title>
<p>A previously healthy 5-year-old boy was admitted to our hospital for evaluation and treatment of consciousness disturbance and fever. The patient had a fever, headache, abdominal pain, and vomiting on the day before admission. On the morning of admission, he spoke incoherently and found it difficult to make eye contact. The patient was referred to our hospital.</p>
<p>On admission, the patient exhibited an altered level of consciousness, with a Glasgow Coma Scale score of 11&#x2013;15 (E4V3-5M4-6). His body temperature, heart rate, and blood pressure were 40.3&#x00B0;C, 160&#x2005;bpm, and 88/62&#x2005;mmHg, respectively. He had bilateral conjunctival injections. Nuchal rigidity and Kernig&#x0027;s sign were positive. Laboratory findings showed a peripheral white blood cell (WBC) count of 24.02&#x2009;&#x00D7;&#x2009;10<sup>9</sup>/L with 87.2&#x0025; neutrophils, a platelet count of 197&#x2009;&#x00D7;&#x2009;10<sup>3</sup>/&#x03BC;l, a serum C-reactive protein (CRP) level of 9.92&#x2005;mg/dl, aspartate aminotransferase (AST) level of 37&#x2005;U/L, serum procalcitonin level of 27.6&#x2005;ng/ml and serum sodium level of 130 mEq/L. A cerebrospinal fluid (CSF) analysis showed mild pleocytosis (mononuclear cells, 10&#x2005;&#x00B5;g/&#x00B5;l), with normal protein and glucose levels. Magnetic resonance imaging (MRI) of the head at admission revealed high-intensity areas in the splenium and genu of the corpus callosum, whereas the apparent diffusion coefficient map revealed low-intensity areas in the same lesions (<xref ref-type="fig" rid="F1">Figure&#x00A0;1</xref>). Although KD was suspected because of fever, conjunctival injection, leukocytosis, and elevated serum CRP levels, echocardiography revealed no abnormalities in the coronary arteries.</p>
<fig id="F1" position="float"><label>Figure 1</label>
<caption><p>Clinical course and the serial changes of laboratory and imaging findings. Segment 1 indicates the right coronary artery. The diameter was measured by echocardiography. IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; CRP, C-reactive protein; SD, standard deviation; MRI, magnetic resonance imaging; DWI, diffusion-weighted imaging.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fped-13-1652101-g001.tif"><alt-text content-type="machine-generated">Graph depicting a patient's temperature over 12 days of illness, along with treatments of IVIG and IVMP indicated by arrows. A timeline shows Glasgow Coma Scale changes, conjunctival injection, lip redness, and membranous desquamation. Serum CRP levels decrease from 9.9 to 0.7 mg/dL, and Z-scores improve from 1.55 to 1.85. MRI images on Day 2 show abnormalities indicated by arrows, with improvement by Day 6.</alt-text>
</graphic>
</fig>
<p>On the first day of admission (the second day of illness), intravenous methylprednisolone for 3 days (30&#x2005;mg/kg/day) and intravenous immunoglobulin (IVIG) (1&#x2005;g/kg/day) for 2 days were initiated as treatment for acute encephalitis (<xref ref-type="fig" rid="F1">Figure&#x00A0;1</xref>). The fever resolved and the patient&#x0027;s consciousness improved on the third day of illness. The abnormal findings were found to have resolved on head MRI performed on the seventh day of illness. Based on the head MRI findings and the clinical course, the patient was diagnosed with MERS.</p>
<p>On the fourth and fifth days of illness, the patient had lip redness and membranous desquamation of the fingers, respectively, and had fever again on the seventh day of illness. Echocardiography revealed dilation of the right coronary artery. Based on the presence of four major KD symptoms and coronary artery dilation, the patient was diagnosed with incomplete KD and treated with high-dose IVIG (2&#x2005;g/kg) and oral aspirin (30&#x2005;mg/kg/day). After treatment, he had defervescence, and the coronary artery showed no further dilation on echocardiography. He was discharged on the 13th day of illness without any neurological or cardiac sequelae.</p>
<p>Serum concentrations of proinflammatory cytokines, including interleukin (IL)-6, IL-18, soluble tumor necrosis factor receptor type II (sTNF-RII), and C-X-C motif chemokine ligand 9 (CXCL9), were measured using enzyme-linked immunosorbent assay kits in the sample collected at admission, as previously reported (<xref ref-type="bibr" rid="B5">5</xref>). The serum levels of IL-6, IL-18, sTNF-RII, and CXCL9 were 150&#x2005;pg/ml [reference range (r.r.)&#x2009;&#x003C;&#x2009;3&#x2005;pg/ml], 1,015&#x2005;pg/ml (r.r.&#x2009;&#x003C;&#x2009;500&#x2005;pg/ml), 10,367&#x2005;pg/ml (r.r. 829&#x2013;2,262&#x2005;pg/ml), and 2,886&#x2005;pg/ml (r.r. 31&#x2013;83&#x2005;pg/ml), respectively. Relative to the serum IL-18 levels, the serum levels of IL-6, sTNF-RII, and CXCL9 were more elevated, and among them, the increase in serum IL-6 levels was particularly notable, which is similar with the pattern observed in KD (<xref ref-type="bibr" rid="B5">5</xref>).</p>
</sec>
<sec id="s3" sec-type="discussion"><title>Discussion and review of the relevant literature</title>
<p>KD can affect various organ systems and may occasionally present unusual clinical features (<xref ref-type="bibr" rid="B2">2</xref>). Some patients are diagnosed with and treated for acute appendicitis, pneumonia, and encephalitis/encephalopathy before being diagnosed with KD (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). The patient was also diagnosed with and treated for MERS prior to the diagnosis of KD. We conducted a PubMed search and reviewed reports presenting the characteristics of patients who developed MERS prior to the diagnosis of KD. A total of five patients have been reported previously (<xref ref-type="table" rid="T1">Table&#x00A0;1</xref>) (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>). When the analysis included the present case, the proportion of female patients (67&#x0025;) and the median age (7 years) were higher than those in a recent nationwide survey of all KD patients in Japan (<xref ref-type="bibr" rid="B12">12</xref>). Previous surveys in Japan have shown that the proportion of female patients with MERS was not high, although the number of patients was relatively small (<xref ref-type="bibr" rid="B4">4</xref>). It is unclear why there was a female predominance in the six patients presented. The median interval between the diagnosis of MERS and KD was 3 days (1&#x2013;11 days). Three patients (50&#x0025;) had CAA complications. None of the patients had any neurological sequelae. In patients with other diseases prior to the diagnosis of KD, the incidence of CAA is considered relatively high, possibly due to the delayed diagnosis of KD (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). In addition, extended inflammatory activity is a risk factor for complications (<xref ref-type="bibr" rid="B8">8</xref>). Of the six patients with MERS, three who developed CAA had a delay before being diagnosed with KD (Patient 1) or were refractory to initial treatment for KD (Patients 3 and 6) (<xref ref-type="table" rid="T1">Table&#x00A0;1</xref>). Clinicians should be aware that the development of MERS may precede the diagnosis of KD in some patients, and patients with an unknown MERS etiology, leukocytosis, and elevated serum CRP levels should be closely observed due to the possibility of KD.</p>
<table-wrap id="T1" position="float"><label>Table 1</label>
<caption><p>The characteristics of the 6 patients developing MERS prior to the diagnosis of KD.</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left">Pt.</th>
<th valign="top" align="center">Age (years)</th>
<th valign="top" align="center">Sex</th>
<th valign="top" align="center">Days of Dx. of KD</th>
<th valign="top" align="center">Days of Dx. of MERS</th>
<th valign="top" align="center">Treatments for MERS</th>
<th valign="top" align="center">Treatments after Dx. of KD</th>
<th valign="top" align="center">Neurological sequelae</th>
<th valign="top" align="center">CAAs</th>
<th valign="top" align="center">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="center">14</td>
<td valign="top" align="left">F</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">6</td>
<td valign="top" align="left">IVIG (400&#x2005;mg/kg/dose)</td>
<td valign="top" align="left">IVIG (1.4&#x2005;g/kg/dose)</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x002B;</td>
<td valign="top" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="center">7</td>
<td valign="top" align="left">F</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">3</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">IVIG (2&#x2005;g/kg/dose), ASA</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">9</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="center">8</td>
<td valign="top" align="left">M</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">1</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">IVIG (2&#x2005;g/kg/dose, 3 times)<break/>ASA, CyA, IFX</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x002B;</td>
<td valign="top" align="center">10</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="center">7</td>
<td valign="top" align="left">F</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">3</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">IVIG (2&#x2005;g/kg/dose), ASA</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">10</td>
</tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="center">2</td>
<td valign="top" align="left">F</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">2</td>
<td valign="top" align="left">None</td>
<td valign="top" align="left">IVIG (2&#x2005;g/kg/dose, twice)<break/>ASA, IVMP, IFX</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">11</td>
</tr>
<tr>
<td valign="top" align="left">6</td>
<td valign="top" align="center">5</td>
<td valign="top" align="left">M</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">2</td>
<td valign="top" align="left">IVIG (1&#x2005;g/kg/dose, twice) IVMP</td>
<td valign="top" align="left">IVIG (2&#x2005;g/kg/dose), ASA</td>
<td valign="top" align="center">&#x2212;</td>
<td valign="top" align="center">&#x002B;<xref ref-type="table-fn" rid="table-fn2"><sup>a</sup></xref></td>
<td valign="top" align="center">Ours</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1"><p>MERS, mild encephalitis/encephalopathy with a reversible splenial lesion; KD, Kawasaki disease; CAA, coronary artery abnormality; IVIG, intravenous immunoglobulin; ASA, aspirin; CyA, cyclosporin A; IFX, infliximab; IVMP, intravenous methylprednisolone; Pt., patient; Dx., diagnosis; Ref., reference;</p></fn>
<fn id="table-fn2"><label><sup>a</sup></label>
<p>Transient dilation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>MERS is a condition characterized by fever, abnormal behavior, disturbance of consciousness, and seizures, primarily occurring post-infection (<xref ref-type="bibr" rid="B4">4</xref>). The pathogenesis of MERS remains unclear; however, several mechanisms have been proposed, including post-infectious cytokine storms, intramyelinic edema caused by systemic inflammatory responses, brain edema associated with hyponatremia, and transient local infiltration of inflammatory cells (<xref ref-type="bibr" rid="B4">4</xref>). In patients with KD, retropharyngeal edema is often found and misdiagnosed as a retropharyngeal abscess (<xref ref-type="bibr" rid="B2">2</xref>). In addition, the histopathological findings of the appendix in patients with KD, primarily diagnosed with acute appendicitis, showed inflammatory changes with edema (<xref ref-type="bibr" rid="B6">6</xref>). As patients with KD are prone to developing edema in various parts of the body, MERS should also be recognized as a complication. In the present case, hyponatremia (130&#x2005;mEq/L) in the acute phase of KD may have contributed to the onset of MERS. Further studies are needed to determine the mechanism underlying the development of MERS in KD.</p>
<p>There have been several reports of cytokine profile analyses of the serum or CSF of patients with KD or MERS. Kaneko et al. compared the cytokine profiles of patients with KD and KD-like diseases and reported that serum IL-6 levels were particularly elevated in those with KD shock syndrome, a more severe form of KD with a high incidence of CAAs (<xref ref-type="bibr" rid="B5">5</xref>). In patients with acute focal bacterial nephritis-associated MERS, various inflammatory cytokines (e.g., IL-6, IL-10, CXCL10, TNF-&#x03B1;, and interferon-&#x03B3;) were elevated in both serum and CSF during the acute phase of the disease and these cytokines returned to normal levels after two weeks (<xref ref-type="bibr" rid="B13">13</xref>). Another study showed that the CSF IL-6 levels were elevated in patients with virus-associated MERS, but the levels were not as high as those in patients with KD or acute focal bacterial nephritis (<xref ref-type="bibr" rid="B14">14</xref>). In a previous report, inflammatory cytokines were measured in only one patient with KD complicated by MERS, and, as in our patient, the serum IL-6 level was high, but the serum IL-18 level was not (<xref ref-type="bibr" rid="B15">15</xref>). Taken together, although IL-6 is elevated even in MERS associated with other diseases and cannot be considered specific to KD, a detailed assessment of its elevation or the measurements of inflammatory cytokines other than IL-6, including IL-18, sTNF-RII, and CXCL9, may be helpful in the diagnosis of KD.</p>
<p>In conclusion, MERS should be considered as a complication of KD. In addition, neurological symptoms caused by MERS may appear as the initial symptoms of KD. Clinicians should maintain a high level of suspicion for KD in children presenting with MERS-like neurological features and elevated inflammatory markers, particularly if classic KD signs emerge later. Further large-scale studies are needed to determine the mechanism underlying the development of MERS in KD and the epidemiology of patients with these two diseases, including the sex ratio.</p>
</sec>
</body>
<back>
<sec id="s4" sec-type="data-availability"><title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s5" sec-type="ethics-statement"><title>Ethics statement</title>
<p>The studies involving humans were approved by Fukuoka Children&#x0027;s Hospital, Fukuoka, Japan. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x0027; legal guardians/next of kin. Written informed consent was obtained from the minor(s)&#x0027; legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s6" sec-type="author-contributions"><title>Author contributions</title>
<p>HY: Writing &#x2013; original draft. SO: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. KM: Writing &#x2013; review &#x0026; editing. NH: Writing &#x2013; review &#x0026; editing. YU: Writing &#x2013; review &#x0026; editing. HK: Writing &#x2013; review &#x0026; editing. RK: Writing &#x2013; review &#x0026; editing. SK: Writing &#x2013; review &#x0026; editing. MS: Writing &#x2013; review &#x0026; editing. TH: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec id="s7" sec-type="funding-information"><title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<ack><title>Acknowledgments</title>
<p>We appreciate the help of Dr. Brian Quinn (Japan Medical Communication, Fukuoka, Japan) in editing the manuscript.</p>
</ack>
<sec id="s8" sec-type="COI-statement"><title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="ai-statement"><title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec id="s10" sec-type="disclaimer"><title>Publisher&#x0027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list><title>References</title>
<ref id="B1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCrindle</surname><given-names>BW</given-names></name><name><surname>Rowley</surname><given-names>AH</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name><name><surname>Bolger</surname><given-names>AF</given-names></name><name><surname>Gewitz</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association</article-title>. <source>Circulation</source>. (<year>2017</year>) <volume>135</volume>:<fpage>e927</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000484</pub-id><pub-id pub-id-type="pmid">28356445</pub-id></citation></ref>
<ref id="B2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Cheah</surname><given-names>CS</given-names></name><name><surname>Suhaini</surname><given-names>SA</given-names></name><name><surname>Azidin</surname><given-names>AH</given-names></name><name><surname>Khoo</surname><given-names>MS</given-names></name><name><surname>Ismail</surname><given-names>NAS</given-names></name><etal/></person-group> <article-title>Clinical manifestations and laboratory findings of Kawasaki disease: beyond the classic diagnostic features</article-title>. <source>Medicina (Kaunas)</source>. (<year>2022</year>) <volume>58</volume>:<fpage>734</fpage>. <pub-id pub-id-type="doi">10.3390/medicina58060734</pub-id><pub-id pub-id-type="pmid">35743997</pub-id></citation></ref>
<ref id="B3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Yashiro</surname><given-names>M</given-names></name><name><surname>Uehara</surname><given-names>R</given-names></name><name><surname>Sadakane</surname><given-names>A</given-names></name><name><surname>Tsuboi</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Epidemiologic features of Kawasaki disease in Japan; results of the 2009&#x2013;2010 nationwide survey</article-title>. <source>J Epidemiol</source>. (<year>2012</year>) <volume>22</volume>:<fpage>216</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.2188/jea.je20110126</pub-id><pub-id pub-id-type="pmid">22447211</pub-id></citation></ref>
<ref id="B4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takanashi</surname><given-names>J</given-names></name></person-group>. <article-title>Two newly proposed infectious encephalitis/encephalopathy syndromes</article-title>. <source>Brain Dev</source>. (<year>2009</year>) <volume>31</volume>:<fpage>521</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2009.02.012</pub-id><pub-id pub-id-type="pmid">19339128</pub-id></citation></ref>
<ref id="B5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Shimbo</surname><given-names>A</given-names></name><name><surname>Irabu</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Furuno</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Clinical significance of serum cytokine profiles for differentiating between Kawasaki disease and its mimickers</article-title>. <source>Cytokine</source>. (<year>2023</year>) <volume>169</volume>:<fpage>156280</fpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2023.156280</pub-id><pub-id pub-id-type="pmid">37356260</pub-id></citation></ref>
<ref id="B6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YN</given-names></name><name><surname>Liu</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Tai</surname><given-names>YL</given-names></name><name><surname>Duh</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><etal/></person-group> <article-title>Appendicitis as a leading manifestation of Kawasaki disease in older children</article-title>. <source>Children (Basel)</source>. (<year>2022</year>) <volume>9</volume>:<fpage>193</fpage>. <pub-id pub-id-type="doi">10.3390/children9020193</pub-id><pub-id pub-id-type="pmid">35204914</pub-id></citation></ref>
<ref id="B7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Jindal</surname><given-names>AK</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Suri</surname><given-names>D</given-names></name><name><surname>Rawat</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Pulmonary presentation of Kawasaki disease-A diagnostic challenge</article-title>. <source>Pediatr Pulmonol</source>. (<year>2018</year>) <volume>53</volume>:<fpage>103</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/ppul.23885</pub-id><pub-id pub-id-type="pmid">28950425</pub-id></citation></ref>
<ref id="B8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itamura</surname><given-names>S</given-names></name><name><surname>Kamada</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>N</given-names></name></person-group>. <article-title>Kawasaki disease complicated with reversible splenial lesion and acute myocarditis</article-title>. <source>Pediatr Cardiol</source>. (<year>2011</year>) <volume>32</volume>:<fpage>696</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-011-9937-4</pub-id><pub-id pub-id-type="pmid">21380714</pub-id></citation></ref>
<ref id="B9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Ushiroda</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Nakatomi</surname><given-names>A</given-names></name><name><surname>Motomura</surname><given-names>H</given-names></name><name><surname>Moriuchi</surname><given-names>H</given-names></name></person-group>. <article-title>Kawasaki disease-associated MERS: pathological insights from SPECT findings</article-title>. <source>Brain Dev</source>. (<year>2012</year>) <volume>34</volume>(<issue>7</issue>):<fpage>605</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2011.09.015</pub-id><pub-id pub-id-type="pmid">22019463</pub-id></citation></ref>
<ref id="B10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takanashi</surname><given-names>J</given-names></name><name><surname>Shirai</surname><given-names>K</given-names></name><name><surname>Sugawara</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Obanai</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>H</given-names></name><etal/></person-group> <article-title>Kawasaki disease complicated by mild encephalopathy with a reversible splenial lesion (MERS)</article-title>. <source>J Neuro Sci</source>. (<year>2012</year>) <volume>315</volume>:<fpage>167</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2011.11.022</pub-id></citation></ref>
<ref id="B11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Imadome</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Effective therapy with infliximab for clinically mild encephalitis/encephalopathy with a reversible splenial lesion in an infant with Kawasaki disease</article-title>. <source>Jpn J Clin Immunol</source>. (<year>2017</year>) <volume>40</volume>:<fpage>190</fpage>&#x2013;<lpage>5</lpage> (<comment>in Japanese</comment>). <pub-id pub-id-type="doi">10.2177/jsci.40.190</pub-id></citation></ref>
<ref id="B12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ae</surname><given-names>R</given-names></name><name><surname>Makino</surname><given-names>N</given-names></name><name><surname>Kuwabara</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>Y</given-names></name><name><surname>Kosami</surname><given-names>K</given-names></name><name><surname>Sasahara</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Incidence of Kawasaki disease before and after the COVID-19 pandemic in Japan: results of the 26th nationwide survey, 2019 to 2020</article-title>. <source>JAMA Pediatr</source>. (<year>2022</year>) <volume>176</volume>:<fpage>1217</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2022.3756</pub-id><pub-id pub-id-type="pmid">36251290</pub-id></citation></ref>
<ref id="B13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Imataka</surname><given-names>G</given-names></name><name><surname>Takase</surname><given-names>N</given-names></name><name><surname>Tada</surname><given-names>H</given-names></name><name><surname>Sakuma</surname><given-names>H</given-names></name><etal/></person-group> <article-title>Increased cytokines/chemokines and hyponatremia as a possible cause of clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with acute focal bacterial nephritis</article-title>. <source>Brain Dev</source>. (<year>2022</year>) <volume>44</volume>:<fpage>30</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2021.07.008</pub-id><pub-id pub-id-type="pmid">34332826</pub-id></citation></ref>
<ref id="B14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>R</given-names></name><name><surname>Tanuma</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Takanashi</surname><given-names>J</given-names></name><name><surname>Nagata</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</article-title>. <source>Brain Dev</source>. (<year>2012</year>) <volume>34</volume>:<fpage>124</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2011.04.004</pub-id><pub-id pub-id-type="pmid">21576007</pub-id></citation></ref>
<ref id="B15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshihara</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Imataka</surname><given-names>G</given-names></name><name><surname>Yoshihara</surname><given-names>S</given-names></name></person-group>. <article-title>Kawasaki disease with mild encephalitis/encephalopathy with reversible splenial lesion in a 2-year-old girl</article-title>. <source>Indian J Pediatr</source>. (<year>2021</year>) <volume>88</volume>:<fpage>718</fpage>. <pub-id pub-id-type="doi">10.1007/s12098-021-03779-5</pub-id><pub-id pub-id-type="pmid">33939172</pub-id></citation></ref></ref-list>
</back>
</article>